Search

Your search keyword '"Famulare, Christopher"' showing total 281 results

Search Constraints

Start Over You searched for: Author "Famulare, Christopher" Remove constraint Author: "Famulare, Christopher"
281 results on '"Famulare, Christopher"'

Search Results

1. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

2. Single-cell mutation analysis of clonal evolution in myeloid malignancies

3. TP53 Y220C mutations in patients with myeloid malignancies

4. Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer

5. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

6. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

9. Acute myeloid leukemia with mixed phenotype is characterized by stemness transcriptomic signatures and limited lineage plasticity

11. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis

12. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

13. Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

14. Supplementary Table from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

15. Supplementary Table 1 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

16. Supplementary Figures from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

17. Supplementary Table 2 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

18. Supplementary Figure from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

19. Supplementary Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

20. Data from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

21. Supplementary Methods from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

22. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

23. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells

24. Supplementary Data from Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial

26. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia

27. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification

28. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia

29. Whole Genome Sequencing Comparison of Acute Myeloid Leukemia at Presentation and Remission Predicts Patient Outcome

30. Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

31. Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

32. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

33. Safety and efficacy of CPX-351 in younger patients (

34. Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

35. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.

36. Clinical and Genomic Characterization of Secondary Acute Myeloid Leukemia with Mixed Phenotype

37. Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

38. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

39. The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations

40. Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

41. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

42. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

43. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells

45. LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

46. Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

47. Immunophenotypic Lineage Assessment By Multiparameter Flow Cytometry Provides More Precise MDS Prognosis

48. Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

49. Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors

50. Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms

Catalog

Books, media, physical & digital resources